Volume 2, Number 3, 279-285, DOI: 10.1007/BF00858677

Published in partnership with the

Logo

International Pediatric Nephrology Association

Treatment of the childhood haemolytic uraemic syndrome with plasma

C. Loirat, E. Sonsino, N. Hinglais, J. P. Jais, P. Landais and J. Fermanian

View Related Documents

Abstract

Seventy-nine children with haemolytic uraemic syndrome (mean age 28 months) were randomly assigned either to a group receiving plasma infusions (plasma group,n=39) or to a group treated conservatively (control group,n=40). The duration of haemolysis, thrombocytopenia and anuria was similar in the two groups. Serum creatinine levels were similar in the two groups at the 1-month follow-up but were higher in the control group at 3 months (plasma group 49±14, control group 66±28 mgrmol/l;P<0.02) and="" at="" 6="" months="" (plasma="" group="" 48±13,="" control="" group="" 63±21="">mgrmol/l;P<0.005). the="" prevalence="" of="" proteinuria="" was="" also="" higher="" in="" the="" control="" group="" at="" the="" 6-month="" follow-up="" (plasma="" group="" 17%,="" control="" group="">P<0.02). however="" differences="" were="" no="" longer="" significant="" after="" 1="" year.="" renal="" tissue="" was="" examined="" in="" 54="" cases="" (plasma="">n=27; control group,n=27). Diffuse cortical necrosis was present in 7 cases in the control group but was absent in the plasma group (P<0.02). taking="" into="" consideration="" the="" higher="" serum="" creatinine="" levels,="" the="" higher="" prevalence="" of="" proteinuria="" during="" the="" first="" 6="" months="" of="" follow-up="" in="" the="" control="" group="" and="" the="" presence="" of="" diffuse="" cortical="" necrosis="" in="" this="" group="" compared="" with="" the="" plasma="" group,="" we="" conclude="" that="" plasma="" infusions="" should="" be="" regarded="" as="" beneficial.="" further="" study="" is="" needed="" to="" determine="" which="" plasma="" fraction="" is="">

Key words  Haemolytic uraemic syndrome - Plasma infusions - Multicentre therapeutic trial - Renal failure - Thrombotic microangiopathy - Cortical necrosis

Fulltext Preview

Image of the first page of the fulltext document